Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INNOVATION: Trastuzumab +/- Pertuzumab in Perioperative Chemotherapy for HER2+ Stomach Cancer
NCT02205047Phase 2Completed
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Jul 2015
- Primary completion
- Dec 2022
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 13
01
Overview
A Phase 2 trial of trastuzumab, pertuzumab in gastric cancer (GC), gastroesophageal junction cancer, sponsored by European Organisation for Research and Treatment of Cancer. Started Jul 2015; status: completed.
02
Drugs
trastuzumabpertuzumab
03
Conditions
gastric cancer (GC)gastroesophageal junction cancer
Beyond the preview
Go deeper on NCT02205047.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02205047.